Welcome to our dedicated page for TC BioPharm (Holdings) plc SEC filings (Ticker: TCBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TC BioPharm (Holdings) plc filings document foreign private issuer reporting, shareholder governance and the public status of its American Depositary Shares and warrants. Form 6-K materials report annual general meeting results, receipt of the U.K. annual report and audited financial statements, directors' remuneration votes, statutory auditor reappointment, audit committee authority over auditor remuneration, and share subdivision or reclassification actions.
The filing record also includes Nasdaq Form 25 disclosure for removal of the company's American Depositary Shares and warrants from listing and registration under Section 12(b) of the Exchange Act. These documents frame TCBPW within the company's warrant capital structure, foreign issuer reporting obligations, governance votes and exchange-listing status.
TC BioPharm (Holdings) plc reported the results of its 2025 Annual General Meeting held on August 29, 2025, where all resolutions were passed on a poll. Shareholders received the company’s annual report and audited financial statements for the year ended December 31, 2024 and approved the Directors’ Remuneration Report for that year. Ecovis Wingrave Yeats was re-appointed as U.K. statutory auditor, and the Audit Committee was authorized to set the auditor’s remuneration for the year ending December 31, 2025.
Shareholders approved a subdivision of each ordinary share of £0.0001 into 1 ordinary share of £0.000001 and 1 B deferred share of £0.000099, and adopted detailed Articles defining B deferred shares as having no dividend, voting, or general meeting rights and only minimal economic rights. The directors were authorized under U.K. law to allot shares or rights up to an aggregate nominal amount of £200,000,000 for five years and to disapply pre-emption rights on such allotments for the same period. The company was also authorized, subject to the new Articles, to make off-market purchases and cancellations of its B deferred shares for up to five years.
What happened: Nasdaq has filed a Form 25 to remove a class of TC BioPharm (Holdings) plc securities from Nasdaq listing and/or registration.
Who and when: The filing names the issuer as TC BioPharm (Holdings) plc and is signed by a Nasdaq hearings advisor on 2025-08-08. The affected classes are the American Depositary Shares and Warrants.